Novo Nordisk

Get 1-1 support on taking charge of your care.

NovoSeven^® RT (coagulation Factor VIIa, recombinant) is an injectable medicine used for: Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with a decreased or absent response to platelet transfusions. Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia.

Managing hemophilia is complex.

Support doesn’t have to be.

Get expert guidance from people who truly understand what you’re going through.

If you’re living with hemophilia, you’re no stranger to challenges. From dealing with difficult symptoms to the emotional struggle of talking to your doctor—the day-to-day can feel overwhelming. But connecting with someone who gets it can make a big difference.

Our Novo Nordisk Rare Blood Community Liaisons (RBCLs) are here for real conversations, whether you want to explore treatment with NovoSeven^® RT, learn about managing Glanzmann’s thrombasthenia or Factor VII deficiency, or are just looking for honest support. With knowledge and fresh perspective, an RBCL can help you take control of your care.

You’re not in this alone. Let’s talk.

Meet your RBCL

Keep scrolling to learn more about NovoSeven^® RT

Important Safety Information for NovoSeven^® RT?

What is the most important information I should know about NovoSeven^® RT?

NovoSeven^® RT may cause serious side effects, including:

•	Serious blood clots that form in veins and arteries with the use of NovoSeven^® RT have been reported

•

Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function

•	Your healthcare provider should monitor you for blood clots during treatment with NovoSeven^® RT

Please click here or scroll below for additional Important Safety Information.

Be ready when bleeds happen.

Discover how NovoSeven^® RT could fit into your hemophilia care plan.

Every moment matters when you have a rare bleeding disorder, and you need a treatment you can trust. Here’s why people turn to NovoSeven^® RT:

Controls bleeds, whenever they happen
Delivers speed when it’s needed
Committed to your health with over 35 years leading hemophilia research and treatment^a

Curious about what NovoSeven® RT could mean for you?

Get to know NovoSeven^® RT

^aCompassionate use, also known as expanded access, began enrolling in 1988; FDA approval received in 1999.

Get connected with your Novo Nordisk Rare Blood Community Liaison (RBCL)

Life with a bleeding disorder can bring challenges. Our RBCLs are experienced and ready to provide you with one-on-one support, including:

	Information about NovoSeven^® RT
	Lifestyle education and resources
	Where to find local events
	Tools to help you manage your bleeding disorder

Reach out to your RBCL

Stay in the know

Be the first to get important updates about NovoSeven^® RT including patient support programs, insurance information through NovoCare^®, and more.

What is NovoSeven^® RT?

NovoSeven^® RT (coagulation Factor VIIa, recombinant) is an injectable medicine used for:

•	Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with a decreased or absent response to platelet transfusions

•	Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia

Important Safety Information (cont’d)

What is the most important information I should know about NovoSeven^® RT? (cont’d)

NovoSeven^® RT may cause serious side effects, including: (cont’d)

•

You should not use NovoSeven^® RT if you have ever had allergic (hypersensitivity) reactions, including severe, whole body reactions (anaphylaxis) to NovoSeven^® RT, any of its ingredients, or mice, hamsters, or cows. Signs of allergic reaction include shortness of breath, rash, itching (pruritus), redness of the skin (erythema), or fainting/dizziness

What should I tell my healthcare provider before using NovoSeven^® RT?

•

Tell your healthcare provider if you have any of the following, as these may increase your risk of blood clots:

◦	congenital hemophilia and are also receiving treatment with aPCCs (activated prothrombin complex concentrates)
◦	are an older patient particularly with acquired hemophilia and receiving other agents to stop bleeding
◦	history of heart or blood vessel diseases

•	Tell your healthcare provider and pharmacist about all the medicines you take, including all prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal remedies

What are the possible side effects of NovoSeven^® RT?

•	The most common and serious side effects are blood clots

•	Tell your healthcare provider about any side effects that bother you or do not go away, and seek medical help right away if you have signs of a blood clot or allergic reaction

Please click here for Prescribing Information.

NovoSeven^® RT is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please do not respond to this email. If you would like to contact us, please click here or call 1-800-727-6500.

UNSUBSCRIBE NOTICE

If you no longer want to receive communications from Novo Nordisk, click here to unsubscribe. You also may call us at 1-877-744-2579 or send us a letter that includes your full contact information (eg, name, email address, phone) to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536. To better understand how Novo Nordisk values your privacy, see our Privacy Statement.